Clostridioides difficile infection (CDI) is the leading cause of health care–associated infections in the United States. The increasing incidence and recurrence rates of CDI together with its associated morbidity and mortality are great concerns. Newer treatment methods, such as narrow-spectrum antibiotics, monoclonal antibodies, and microbial replacement therapies, are being developed and implemented. We searched PubMed to identify published literature from 2010 to 2018 using the following keywords: Clostridium difficile, treatment, and therapy. Cited references were also used to identify relevant literature. This review focuses on the current standard of therapy and emerging therapies for CDI and summarizes the updated guidelines on treatment of CDI.

在美国，难辨梭状芽孢杆菌感染（CDI）是与卫生保健相关的感染的主要原因。CDI的发病率和复发率不断上升，其相关的发病率和死亡率也令人担忧。正在开发和实施更新的治疗方法，例如窄谱抗生素，单克隆抗体和微生物替代疗法。我们使用以下关键词搜索PubMed以识别2010年至2018年发表的文献：艰难梭菌（Clostridium difficile），治疗和疗法。被引用的参考文献也被用来识别相关文献。这篇综述着重于CDI的当前治疗标准和新兴疗法，并总结了CDI治疗的最新指南。